Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2015, Vol. 20 ›› Issue (2): 217-222.

Previous Articles     Next Articles

Advances in multi-targeted anti-tumor mechanisms of β-phenethyl isothiocyanate

ZHANG Xue1, WU Lan-xiang1, ZHANG Tao-lan2, WEN Chun-jie1, FU Li-juan1, ZHOU Hong-hao1   

  1. 1Institute of Life Sciences, Chongqing Medical University, Chongqing, 400016, China;
    2Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China;
    3Institute of Chinical Pharmacology, Cantral South University; Hunan Laboratony of Phamacogentics Changsha, 410078; Hunan, China
  • Received:2013-09-03 Revised:2014-06-23 Online:2015-02-26 Published:2015-03-20

Abstract: Cancer has very high mortality and increasing prevalence rates. And cancer therapy has become an important research topic in the scientific community and the medical profession. Phenethyl isothiocyanate (PEITC) is one of the most widely investigated isothiocyanates from the crucifers. Increasing evidences from epidemiological and pathological studies suggest that PEITC can induce cancer cell cycle arrest and apoptosis. It exerts its chemopreventive effect through regulation of diverse molecular mechanisms. Here, we summarize recent data regarding the multi-targeted anti-cancer activity mechanisms and potential molecular targets of PEITC.

Key words: cancer therapies, β-phenylethyl isothiocyanate, molecular mechanisms

CLC Number: